{'fraction_non_alphanumeric': 0.02586713697824809, 'fraction_numerical': 0.02586713697824809, 'mean_word_length': 4.848797250859106, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Resorption of the diabetic cystoid macular edema after intravitreal triamcinolon acetonide injection depending on compensation of diabetes and systemic hypertension].

PURPOSE
The aim of the study was to evaluate the effect of the intravitreal administration of triamcinolon acetonide depending on patients' HbAlc and blood pressure levels. The presence of edema, its resorption, and the duration of the edema free macula during the follow-up period were evaluated.


METHODS
A total of 80 eyes of 68 patients with persistent diabetic macular edema after grid laser photocoagulation were included in the study. The follow-up period of each eye was 6 months. The group of patients was divided into four subgroups according to the blood pressure levels (up to 120/80 mm Hg, 120/80-140/90 mm Hg, 140/90-180/110 mm Hg, and higher than 180/110 mm Hg) and into two subgroups according to the HbA1c levels (up to 6% and above 6%). The dose of 4 mg (0.1 ml) of triamcinolon acetonide suspension (TRIAM INJEKT) was used in the standard transconjuctival intravitreal injection. The site of injection was located superotemporaly 4 mm behind the limbus.


RESULTS
The cystoid edema resolved in all eyes treated in the study. The patients with excellent controlled blood pressure maintained the edema free macula during the whole follow-up period. The patients with poorly controlled blood pressure experienced recurrence of the edema during follow up period. The HbAlc level did not influence the effect of the intravitreal triamcinolon administration.


CONCLUSION
The results achieved in the study allow us to identify more accurately the patients, who may profit from the intravitreal triamcinolone injection.